Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10954712 | 0.85 | TDP1 (0.39) | POLBKMT2AMEN1TDP1NR1I2 | |
| SCHEMBL1629451 | 0.83 | POLB (0.45) | POLBKMT2AMEN1TDP1CYP3A4 | |
| SCHEMBL2720324 | 0.81 | POLB (0.44) | POLBKMT2AMEN1TDP1TSHR | |
| SCHEMBL1631353 | 0.81 | POLB (0.44) | POLBKMT2AMEN1TDP1CYP3A4 | |
| SCHEMBL4223022 | 0.81 | POLB (0.44) | POLBKMT2AMEN1TDP1NR1I2 | |
| SCHEMBL6253586 | 0.80 | POLB (0.67) | POLBKMT2AMEN1TDP1NR1I2 | |
| SCHEMBL3242752 | 0.80 | POLB (0.43) | POLBKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12723907 | 0.80 | POLB (0.43) | POLBKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3076848 | 0.79 | TDP1 (0.49) | POLBKMT2AMEN1TDP1NR1I2 | |
| SCHEMBL28758808 | 0.78 | TDP1 (0.44) | POLBKMT2AMEN1TDP1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183260-B1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | IDENIX PHARMACEUTICALS INC (US) | 2011-06-01 | — | — | EP | disclosed |
| US-7932240-B2 | Phosphadiazine HCV polymerase inhibitors IV | IDENIX PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932240-B2 | Phosphadiazine HCV polymerase inhibitors IV | IDENIX PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932240-B2 | Phosphadiazine HCV polymerase inhibitors IV | IDENIX PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2183260-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | IDENIX Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090081158-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090081158-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090081158-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| WO-2009032180-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032180-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090081158-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | POLI, ITPA, POLR2H | POLB 28/4885KMT2A 1696/4885MEN1 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.